Evan D Kharasch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5560811/publications.pdf

Version: 2024-02-01

114 papers 4,282 citations

39 h-index 61 g-index

115 all docs

115 docs citations

115 times ranked

4040 citing authors

#	Article	IF	CITATIONS
1	Authorship and Publication Matters: Reply. Anesthesiology, 2022, 136, 245-245.	2.5	O
2	Opioids and Public Health: The Prescription Opioid Ecosystem and Need for Improved Management. Anesthesiology, 2022, 136, 10-30.	2.5	31
3	Anesthetic MAC: Origin, Utility, and Nomenclature Revisited. Anesthesiology, 2022, 136, 885-887.	2.5	O
4	Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in pediatric disposition. British Journal of Clinical Pharmacology, 2022, , .	2.4	1
5	Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans. British Journal of Clinical Pharmacology, 2021, 87, 516-526.	2.4	4
6	Opioid-free Anesthesia: Time to Regain Our Balance. Anesthesiology, 2021, 134, 509-514.	2.5	37
7	Gold Nanorod Size-Dependent Fluorescence Enhancement for Ultrasensitive Fluoroimmunoassays. ACS Applied Materials & Enhancement for Ultrasensitive Fluoroimmunoassays.	8.0	29
8	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 2021, 110, 888-896.	4.7	212
9	Opioid-free Anesthesia: Reply. Anesthesiology, 2021, 135, 759-760.	2.5	2
10	Anesthesiology: Reflecting and Leading. Anesthesiology, 2021, 135, 551-554.	2.5	1
11	Peer Review Matters: Research Quality and the Public Trust. Anesthesiology, 2021, 134, 1-6.	2.5	36
12	Comment on "Postoperative Opioid Prescribing and Pain― Annals of Surgery, 2020, 271, e125.	4.2	1
13	Innovation in Clinical Research Regulation. Anesthesiology, 2020, 132, 1-4.	2.5	O
14	Stereoselective Steady‧tate Disposition and Bioequivalence of Brand and Generic Bupropion in Adults. Clinical Pharmacology and Therapeutics, 2020, 108, 1036-1048.	4.7	2
15	The metabotropic glutamate receptor 5 negative allosteric modulator fenobam: pharmacokinetics, side effects, and analgesic effects in healthy human subjects. Pain, 2020, 161, 135-146.	4.2	10
16	Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants. Drug Metabolism and Disposition, 2020, 48, 438-445.	3.3	13
17	Toward precision prescribing for methadone: Determinants of methadone deposition. PLoS ONE, 2020, 15, e0231467.	2.5	14
18	Rational Perioperative Opioid Management in the Era of the Opioid Crisis. Anesthesiology, 2020, 132, 603-605.	2.5	34

#	Article	IF	Citations
19	Persistent Postoperative Opioid Use. Anesthesiology, 2020, 132, 1304-1306.	2.5	11
20	Novel Coronavirus 2019 and Anesthesiology. Anesthesiology, 2020, 132, 1289-1291.	2.5	10
21	Uncertainty and Certainty. Anesthesiology, 2020, 133, 1-4.	2.5	6
22	Perioperative Gabapentinoids. Anesthesiology, 2020, 133, 251-254.	2.5	48
23	Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition. Clinical Pharmacology and Therapeutics, 2019, 105, 142-152.	4.7	17
24	Bioplasmonic paper–based assay for perilipin-2 non-invasively detects renal cancer. Kidney International, 2019, 96, 1417-1421.	5.2	16
25	Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. Neurolmage: Clinical, 2019, 21, 101679.	2.7	11
26	Methadone Disposition: Implementing Lessons Learned. Journal of Clinical Pharmacology, 2019, 59, 1044-1048.	2.0	14
27	Strainâ€specific altered nicotine metabolism in 3,3′â€diindolylmethane (DIM) exposed mice. Biopharmaceutics and Drug Disposition, 2019, 40, 188-194.	1.9	2
28	Nicotine oxidation by genetic variants of <scp>CYP</scp> 2B6 and in human brain microsomes. Pharmacology Research and Perspectives, 2019, 7, e00468.	2.4	17
29	Understanding Research Methods and the Readers' Toolbox: A New Article Type. Anesthesiology, 2019, 130, 181-182.	2.5	2
30	Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. Drug Metabolism and Disposition, 2019, 47, 1195-1205.	3.3	28
31	Trusted Evidence: Discovery to Practice. Anesthesiology, 2019, 130, 1-2.	2.5	2
32	Observations and Observational Research. Anesthesiology, 2019, 131, 1-4.	2.5	9
33	Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches. Molecular Pharmaceutics, 2019, 16, 898-906.	4.6	30
34	Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 1164-1174.	4.7	10
35	The Challenges of Translation. Anesthesiology, 2018, 128, 693-696.	2.5	14
36	Ultrarobust Biochips with Metal–Organic Framework Coating for Point-of-Care Diagnosis. ACS Sensors, 2018, 3, 342-351.	7.8	29

3

#	Article	IF	Citations
37	How central is central poststroke pain? The role of afferent input in poststroke neuropathic pain: a prospective, open-label pilot study. Pain, 2018, 159, 1317-1324.	4.2	40
38	Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase. Anesthesiology, 2018, 129, 756-768.	2.5	18
39	Editor's Note: Anesthesiology 2018. Anesthesiology, 2018, 129, 1-4.	2.5	4
40	Journal-related Activities and Other Special Activities at the 2018 American Society of Anesthesiologists Meeting. Anesthesiology, 2018, 129, 634-643.	2.5	0
41	Metalâ€Organic Framework Encapsulation Preserves the Bioactivity of Protein Therapeutics. Advanced Healthcare Materials, 2018, 7, e1800950.	7.6	61
42	Add-on plasmonic patch as a universal fluorescence enhancer. Light: Science and Applications, 2018, 7, 29.	16.6	58
43	Current Concepts in Methadone Metabolism and Transport. Clinical Pharmacology in Drug Development, 2017, 6, 125-134.	1.6	67
44	Amplification of Refractometric Biosensor Response through Biomineralization of Metal–Organic Framework Nanocrystals. Advanced Materials Technologies, 2017, 2, 1700023.	5.8	6
45	Single Molecule Force Spectroscopy to Compare Natural versus Artificial Antibody–Antigen Interaction. Small, 2017, 13, 1604255.	10.0	21
46	Metalâ€Organic Framework as a Protective Coating for Biodiagnostic Chips. Advanced Materials, 2017, 29, 1604433.	21.0	56
47	Errors and Integrity in Seeking and Reporting Apparent Research Misconduct. Anesthesiology, 2017, 127, 733-737.	2.5	14
48	Rapid, Pointâ€ofâ€Care, Paperâ€Based Plasmonic Biosensor for Zika Virus Diagnosis. Advanced Biology, 2017, 1, e1700096.	3.0	36
49	Editor's Note: A <scp>nesthesiology</scp> 2017. Anesthesiology, 2017, 127, 1-2.	2.5	3
50	Reply to comment on: Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26343.	1.5	0
51	Changes. Anesthesiology, 2016, 125, 4-6.	2.5	6
52	Wherefore Gabapentinoids?. Anesthesiology, 2016, 124, 10-12.	2.5	21
53	Changes. Anesthesiology, 2016, 125, 1-3.	2.5	1
54	Perioperative Opioids and Public Health. Anesthesiology, 2016, 124, 960-965.	2.5	108

#	Article	IF	CITATIONS
55	Misidentification of Bupropion Glucuronide Metabolites and Re-evaluation of Metabolite Pharmacokinetics. Drug Metabolism and Disposition, 2016, 44, 1851-1851.	3.3	1
56	PEGylated Artificial Antibodies: Plasmonic Biosensors with Improved Selectivity. ACS Applied Materials & Samp; Interfaces, 2016, 8, 23509-23516.	8.0	40
57	Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. Pediatric Blood and Cancer, 2016, 63, 2123-2130.	1.5	19
58	Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance. Anesthesiology, 2016, 125, 1103-1112.	2.5	46
59	Development, validation and application of a comprehensive stereoselective LC/MS–MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1027, 239-253.	2.3	13
60	Development and validation of a high-throughput stereoselective LC–MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1017-1018, 101-113.	2.3	19
61	Opioid Half-lives and Hemlines. Anesthesiology, 2015, 122, 969-970.	2.5	17
62	Steroid Anesthesia Revisited. Anesthesia and Analgesia, 2015, 120, 983-984.	2.2	10
63	Methadone Pharmacogenetics. Anesthesiology, 2015, 123, 1142-1153.	2.5	111
64	Bioâ€Enabled Gold Superstructures with Builtâ€In and Accessible Electromagnetic Hotspots. Advanced Healthcare Materials, 2015, 4, 1502-1509.	7.6	21
65	Influence of HIV antiretrovirals on methadone N-demethylation and transport. Biochemical Pharmacology, 2015, 95, 115-125.	4.4	15
66	Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma. JAMA Oncology, 2015, 1, 204.	7.1	86
67	Urine Aquaporin 1 and Perilipin 2 Differentiate Renal Carcinomas From Other Imaged Renal Masses and Bladder and Prostate Cancer. Mayo Clinic Proceedings, 2015, 90, 35-42.	3.0	64
68	Differences in Methadone Metabolism by CYP2B6 Variants. Drug Metabolism and Disposition, 2015, 43, 994-1001.	3.3	56
69	Effect of HAART on Brain Organization and Function in HIV-Negative Subjects. Journal of NeuroImmune Pharmacology, 2015, 10, 517-521.	4.1	15
70	Peptide Functionalized Gold Nanorods for the Sensitive Detection of a Cardiac Biomarker Using Plasmonic Paper Devices. Scientific Reports, 2015, 5, 16206.	3.3	82
71	Peptide Functionalized Gold Nanorods for the Sensitive Detection of a Cardiac Biomarker Using Plasmonic Paper Devices. Scientific Reports, 2015, 5, .	3.3	15
72	Bioplasmonic calligraphy for multiplexed label-free biodetection. Biosensors and Bioelectronics, 2014, 59, 208-215.	10.1	26

#	Article	IF	CITATIONS
73	Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochemical Pharmacology, 2014, 91, 109-118.	4.4	38
74	Automated radiochemical synthesis and biodistribution of [11C]l- $\hat{l}\pm$ -acetylmethadol ([11C]LAAM). Applied Radiation and Isotopes, 2014, 91, 135-140.	1.5	4
75	Characterizing the abuse potential of loperamide via physiologicallyâ€based pharmacokinetic/pharmacodynamic modeling and simulation (1053.6). FASEB Journal, 2014, 28, 1053.6.	0.5	1
76	Methadone <i>N</i> -Demethylation by the Common <i>CYP2B6</i> Allelic Variant CYP2B6.6. Drug Metabolism and Disposition, 2013, 41, 709-713.	3.3	42
77	Role of Cytochrome P4502B6 in Methadone Metabolism and Clearance. Journal of Clinical Pharmacology, 2013, 53, 305-313.	2.0	62
78	Cytochrome P4503A Does Not Mediate the Interaction between Methadone and Ritonavir-Lopinavir. Drug Metabolism and Disposition, 2013, 41, 2166-2174.	3.3	21
79	Sleeping to Survive?. Anesthesiology, 2013, 119, 755-756.	2.5	3
80	Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A). Anesthesiology, 2012, 116, 432-447.	2.5	35
81	Perioperative Pharmacokinetics of Methadone in Adolescents. Anesthesiology, 2011, 115, 1153-1161.	2.5	51
82	Effect of Rifampicin on S-ketamine and S-norketamine Plasma Concentrations in Healthy Volunteers after Intravenous S-ketamine Administration. Anesthesiology, 2011, 114, 1435-1445.	2.5	44
83	Intraoperative Methadone. Anesthesia and Analgesia, 2011, 112, 13-16.	2.2	95
84	The Metabotropic Glutamate Receptor Subtype 5 Antagonist Fenobam Is Analgesic and Has Improved in Vivo Selectivity Compared with the Prototypical Antagonist 2-Methyl-6-(phenylethynyl)-pyridine. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 834-843.	2.5	69
85	Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug Transport. Anesthesiology, 2009, 110, 660-672.	2.5	77
86	Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug and Alcohol Dependence, 2009, 101, 158-168.	3.2	67
87	Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver Microsomes. Pharmaceutical Research, 2008, 25, 1405-1411.	3.5	46
88	Mutations in a Molecule: The Virtues of Antagonism. Mayo Clinic Proceedings, 2008, 83, 1083-1086.	3.0	0
89	Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by Ritonavir. Antimicrobial Agents and Chemotherapy, 2008, 52, 1663-1669.	3.2	78
90	Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity. Journal of Clinical Pharmacology, 2008, 48, 464-474.	2.0	60

#	Article	IF	Citations
91	Molecular Characterization of CYP2B6 Substrates. Current Drug Metabolism, 2008, 9, 363-373.	1.2	46
92	Role of CYP2B6 in Stereoselective Human Methadone Metabolism. Anesthesiology, 2008, 108, 363-374.	2.5	174
93	Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 389-399.	2.5	102
94	Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 857, 67-75.	2.3	82
95	New Insights into the Mechanism of Methoxyflurane Nephrotoxicity and Implications for Anesthetic Development (Part 1). Anesthesiology, 2006, 105, 726-736.	2.5	20
96	New Insights into the Mechanism of Methoxyflurane Nephrotoxicity and Implications for Anesthetic Development (Part 2). Anesthesiology, 2006, 105, 737-745.	2.5	24
97	Gene Expression Profiling of Nephrotoxicity from the Sevoflurane Degradation Product Fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl Ether ("Compound Aâ€) in Rats. Toxicological Sciences, 2006, 90, 419-431.	3.1	61
98	Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimally Invasive and Noninvasive Probes for Hepatic and First-Pass CYP3A Activity. Journal of Clinical Pharmacology, 2005, 45, 1187-1197.	2.0	24
99	Influence of Sevoflurane on the Metabolism and Renal Effects of Compound A in Rats. Anesthesiology, 2005, 103, 1183-1188.	2.5	28
100	Paradoxical Role of Cytochrome P450 3A in the Bioactivation and Clinical Effects of Levo-??-Acetylmethadol. Clinical Pharmacokinetics, 2005, 44, 731-751.	3.5	13
101	Evaluation of First-Pass Cytochrome P4503A (CYP3A) and P-Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination. Journal of Clinical Pharmacology, 2005, 45, 79-88.	2.0	27
102	Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clinical Pharmacology and Therapeutics, 2004, 76, 250-269.	4.7	213
103	Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis. Clinical Pharmacology and Therapeutics, 2004, 76, 452-466.	4.7	107
104	Perioperative COX-2 Inhibitors: Knowledge and Challenges. Anesthesia and Analgesia, 2004, 98, 1-3.	2.2	15
105	Quinidine as a Probe for the Role of P-Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl. Journal of Clinical Pharmacology, 2004, 44, 224-233.	2.0	72
106	Influence of Age on the Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Fentanyl Citrate. Anesthesiology, 2004, 101, 738-743.	2.5	48
107	Influence of Hepatic and Intestinal Cytochrome P4503A Activity on the Acute Disposition and Effects of Oral Transmucosal Fentanyl Citrate. Anesthesiology, 2004, 101, 729-737.	2.5	60
108	Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity. Clinical Pharmacology and Therapeutics, 2003, 73, 199-208.	4.7	26

#	Article	IF	CITATION
109	Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clinical Pharmacology and Therapeutics, 2003, 74, 543-554.	4.7	137
110	Comparison of Amsorb®, Sodalime, and Baralyme®Degradation of Volatile Anesthetics and Formation of Carbon Monoxide and Compound A in Swine In VivoÂ. Anesthesiology, 2002, 96, 173-182.	2.5	67
111	Intraindividual Variability in Male Hepatic CYP3A4 Activity Assessed by Alfentanil and Midazolam Clearance. Journal of Clinical Pharmacology, 1999, 39, 664-669.	2.0	49
112	Single-dose disulfiram does not inhibit CYP2A6 activity*. Clinical Pharmacology and Therapeutics, 1998, 64, 39-45.	4.7	22
113	Does Ketamine-Mediated N-methyl-D-aspartate Receptor Antagonism Cause Schizophrenia-like Oculomotor Abnormalities?. Neuropsychopharmacology, 1998, 19, 434-444.	5.4	79
114	Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clinical Pharmacology and Therapeutics, 1993, 53, 643-650.	4.7	114